Virtu Financial LLC lowered its position in Zoetis Inc (NYSE:ZTS) by 29.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,479 shares of the company’s stock after selling 1,437 shares during the period. Virtu Financial LLC’s holdings in Zoetis were worth $433,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in ZTS. Nuveen Asset Management LLC lifted its position in shares of Zoetis by 40,874.9% in the second quarter. Nuveen Asset Management LLC now owns 7,078,826 shares of the company’s stock worth $803,376,000 after buying an additional 7,061,550 shares during the last quarter. Stonehage Fleming Financial Services Holdings Ltd bought a new position in shares of Zoetis in the 2nd quarter valued at approximately $133,113,000. Bank of New York Mellon Corp lifted its holdings in Zoetis by 9.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 4,420,261 shares of the company’s stock worth $501,654,000 after purchasing an additional 383,799 shares during the last quarter. Vanguard Group Inc. boosted its position in Zoetis by 1.0% during the second quarter. Vanguard Group Inc. now owns 36,765,577 shares of the company’s stock worth $4,172,526,000 after purchasing an additional 346,167 shares during the period. Finally, Natixis boosted its position in Zoetis by 147.1% during the second quarter. Natixis now owns 547,078 shares of the company’s stock worth $62,088,000 after purchasing an additional 325,661 shares during the period. Hedge funds and other institutional investors own 90.17% of the company’s stock.
In other news, EVP Roxanne Lagano sold 4,463 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $118.99, for a total transaction of $531,052.37. Following the sale, the executive vice president now directly owns 33,190 shares of the company’s stock, valued at $3,949,278.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Clinton A. Jr. Lewis sold 6,123 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $128.62, for a total transaction of $787,540.26. Following the completion of the sale, the executive vice president now directly owns 39,141 shares of the company’s stock, valued at approximately $5,034,315.42. The disclosure for this sale can be found here. In the last three months, insiders have sold 125,600 shares of company stock worth $15,021,964. Insiders own 0.29% of the company’s stock.
Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, November 7th. The company reported $0.94 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.06. Zoetis had a return on equity of 70.78% and a net margin of 23.76%. The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.58 billion. During the same period last year, the company posted $0.83 earnings per share. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. On average, equities research analysts predict that Zoetis Inc will post 3.6 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Shareholders of record on Tuesday, October 22nd were issued a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date was Monday, October 21st. Zoetis’s dividend payout ratio is currently 21.09%.
Several equities analysts have commented on ZTS shares. Argus set a $140.00 price target on Zoetis and gave the company a “buy” rating in a report on Wednesday, September 4th. Credit Suisse Group set a $138.00 target price on Zoetis and gave the stock a “buy” rating in a research report on Friday, October 11th. Goldman Sachs Group assumed coverage on shares of Zoetis in a research note on Monday, September 9th. They issued a “conviction-buy” rating and a $145.00 target price on the stock. Stifel Nicolaus set a $140.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research report on Friday, September 13th. Finally, ValuEngine cut shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Zoetis currently has an average rating of “Buy” and a consensus target price of $125.20.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
See Also: What is the Consumer Price Index (CPI)?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.